Halozyme Therapeutics, Inc. $HALO Shares Sold by Aberdeen Group plc

Key Points

• Aberdeen Group plc reduced its stake in Halozyme Therapeutics, selling 28,247 shares and owning approximately 0.06% of the company valued at $4,083,000.
• Research analysts have varying opinions on Halozyme Therapeutics, with target prices ranging from $55.00 to $91.00 and multiple ratings of "Buy" and "Hold."
• The company reported earnings of $1.54 per share in its last quarter, exceeding estimates and indicating a 40.8% revenue growth year-over-year.

Aberdeen Group plc lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 26.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 78,490 shares of the biopharmaceutical company's stock after selling 28,247 shares during the period. Aberdeen Group plc owned about 0.06% of Halozyme Therapeutics worth $4,083,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wealth Preservation Advisors LLC acquired a new position in Halozyme Therapeutics during the 1st quarter worth approximately $32,000. SVB Wealth LLC acquired a new position in shares of Halozyme Therapeutics in the 1st quarter valued at $33,000. Bessemer Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 207 shares in the last quarter. Brooklyn Investment Group boosted its holdings in shares of Halozyme Therapeutics by 1,558.1% in the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 670 shares in the last quarter. Finally, Park Place Capital Corp boosted its holdings in shares of Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

Analyst Ratings Changes

HALO has been the subject of several research analyst reports. JMP Securities upped their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a report on Wednesday, August 6th. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 target price for the company. Leerink Partners upgraded shares of Halozyme Therapeutics from an "underperform" rating to a "market perform" rating and set a $70.00 target price for the company in a report on Tuesday. Morgan Stanley upped their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a report on Monday, August 18th. Finally, Zacks Research cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, October 6th. Six analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $73.00.

Halozyme Therapeutics Stock Up 0.8%

Shares of NASDAQ:HALO opened at $66.88 on Friday. The stock has a market cap of $7.82 billion, a P/E ratio of 15.30, a P/E/G ratio of 0.35 and a beta of 1.16. The firm has a fifty day moving average price of $71.48 and a 200 day moving average price of $62.06. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. Halozyme Therapeutics's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the company's stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the transaction, the chief financial officer owned 24,306 shares in the company, valued at approximately $1,840,207.26. This represents a 45.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total transaction of $1,507,000.00. Following the transaction, the chief executive officer owned 733,719 shares of the company's stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 108,227 shares of company stock worth $7,779,595. 2.40% of the stock is owned by insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.